Quarterly report pursuant to Section 13 or 15(d)

Research and License Agreements (Details Narrative)

v3.21.1
Research and License Agreements (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended
Jun. 30, 2020
Jun. 30, 2020
Feb. 28, 2021
Nov. 30, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2019
Dec. 31, 2018
Jun. 30, 2018
Mar. 31, 2021
Mar. 30, 2021
Mar. 31, 2020
Mar. 30, 2020
Dec. 31, 2020
Research and development                   $ 3,499,373   $ 238,059    
Product sales                   1,899,496   1,456,755    
Collaborative Research Revenue [Member]                            
Product sales                     45,000    
License Revenue [Member]                            
Product sales                   478,654      
University of Louisville Research Foundation [Member] | Minimum [Member] | Royalties and Non-Royalty Sublicensee Income [Member]                            
Shortfall payments $ 5,000                          
University of Louisville Research Foundation [Member] | Maximum [Member] | Royalties and Non-Royalty Sublicensee Income [Member]                            
Shortfall payments   $ 50,000                        
Prediction Biosciences SAS [Member] | Collaborative Research Revenue [Member]                            
Product sales                   45,000   0    
Sekisui Diagnostics, LLC [Member]                            
Product sales                     $ 1,000,000   $ 1,000,000  
Yi Xin Zhen Duan Jishu Ltd [Member]                            
Product sales                   38,000        
Deferred revenue                   420,000       $ 250,000
Yi Xin Zhen Duan Jishu Ltd [Member] | License Revenue [Member]                            
Product sales                   479,000        
STA Pharmaceutical Co Ltd [Member]                            
Upfront deposit                           $ 1,100,000
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member]                            
Payment of convertible promissory note         $ 50,000       $ 50,000          
Reimbursement of research expenses         805,000       805,000          
Reimbursement patent cost         $ 200,000       $ 200,000          
Agreement term payment, description         In addition, the Company has agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization of anti-nucleolin agent-conjugated nanoparticles of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the last to expire of the licensed patents, (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter)       In addition, the Company has agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization of anti-nucleolin agent-conjugated nanoparticles of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the last to expire of the licensed patents, (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter)          
Licensed product sales, revenue         $ 500,000,000       $ 500,000,000          
Milestone payment for marketing expenses         500,000       500,000          
Research and development                   107,000   108,000    
License costs                   46,000   0    
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Licensed Product Sales [Member]                            
Regulatory marketing approval, expenses         500,000   $ 5,000,000   500,000          
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Phase 1 Clinical Trial [Member]                            
Milestone payment         100,000   50,000   100,000          
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Phase 2 Clinical Trial [Member]                            
Milestone payment         200,000   100,000   200,000          
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Phase 3 Clinical Trial [Member]                            
Milestone payment         350,000   150,000   350,000          
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Minimum [Member]                            
Milestone payment         100,000       100,000          
Shortfall payments         10,000       10,000          
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Maximum [Member]                            
Milestone payment         5,000,000       5,000,000          
Shortfall payments         $ 50,000       $ 50,000          
Sponsored Research and License Agreement [Member]                            
Research and development                   62,000   0    
Minimum annual royalties                   0   10,000    
License costs                   36,000   0    
Sponsored Research and License Agreement [Member] | University of Louisville Research Foundation [Member]                            
Reimbursement of research expenses     $ 1,400,000       693,000              
Reimbursement patent cost             $ 112,000              
Agreement term payment, description             In addition, the Company has agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the licensed patent, and 2.5% (on net sales for any sales not covered by Licensed Patents), (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter),              
Regulatory marketing approval, expenses             $ 300,000              
Licensed product sales, revenue             500,000,000              
Sponsored Research and License Agreement [Member] | University of Louisville Research Foundation [Member] | Minimum [Member]                            
Milestone payment             50,000              
Sponsored Research and License Agreement [Member] | University of Louisville Research Foundation [Member] | Maximum [Member]                            
Milestone payment             5,000,000              
License Agreement [Member] | University of Louisville Research Foundation [Member]                            
License costs                   0   0    
Upfront license fee $ 24,000 $ 24,000       $ 24,000                
ULRF license agreement description           In addition, the Company has agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the licensed patent, and 2.5% (on net sales for any sales not covered by Licensed Patents), (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for costs associated with the preparation, filing, prosecution and maintenance of licensed patents, incurred prior to June 2020, and (iv) payments ranging from $50,000 to $5,000,000 upon the achievement of certain regulatory and commercial milestones. Milestone payments for the first therapeutic indication would be $50,000 for first dosing in a Phase 1 clinical trial, $100,000 for first dosing in a Phase 2 clinical trial, $150,000 for first dosing in a Phase 3 clinical trial, $300,000 for regulatory marketing approval and $5,000,000 upon achieving a cumulative $500,000,000 of Licensed Product sales.                
Sponsored research expense                   69,000   0    
License Agreement [Member] | University of Louisville Research Foundation [Member] | Minimum [Member]                            
Upfront license fee             20,000              
License Agreement [Member] | University of Louisville Research Foundation [Member] | Maximum [Member]                            
Research and development       $ 430,000   $ 250,000                
Upfront license fee             $ 100,000              
License Agreement [Member] | Advanced Cancer Therapeutics, LLC [Member]                            
Licensed product sales, revenue               $ 3,000,000            
License costs                   $ 2,000   $ 0    
Proceeds from convertible promissory note               $ 25,000            
Agreement description               The Company entered into a license agreement with Advanced Cancer Therapeutics, LLC ("ACT"), granting the Company exclusive rights to develop and commercialize QN-165, an aptamer-based drug candidate. In return, ACT received a $25,000 convertible promissory note in payment of an upfront license fee, which was subsequently converted into the Company's common stock. In addition, the Company agreed to pay ACT (i) royalties, on net sales associated with the commercialization of QN-165, of 2% (only if patent-covered and only on net sales above a cumulative $3,000,000) or 1% (if not patent-covered, but only on net sales above a cumulative $3,000,000), until the 15th anniversary of the ACT license agreement and (ii) milestone payments of $100,000 for the Company raising a cumulative total of $2,000,000 in new equity financing after the date of the ACT license agreement, $100,000 upon any first QN-165-based licensed product receiving the CE Mark or similar FDA status, and $500,000 upon cumulative worldwide QN-165-based licensed product net sales reaching $3,000,000.            
Milestone payment               $ 100,000            
Cumulative amount               2,000,000            
License Agreement [Member] | Advanced Cancer Therapeutics, LLC [Member] | CE Mark [Member]                            
Milestone payment               100,000            
Cumulative amount               $ 500,000